Who
Shawn Singh
President and CEO
Company insider
Files Form 4 as: President and CEO, Vistagen Therapeutics; President (interim), Echo Therapeutics.
In numbers
- Trades disclosed
- 117
- Buys
- 1
- Sells
- 0
- Bought
- $102K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 14 Sep 2007
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Code A | $7,07336,818 at $0.1921 | filing |
| 30 Jun 2026filed 2 Jul 2026 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Code A | $6,99536,818 at $0.19 | filing |
| 7 Apr 2026filed 9 Apr 2026 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,732 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —71,268 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,732 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —71,268 at $0.00 | filing |
| 30 Jun 2025filed 1 Jul 2025 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K7,541 at $1.70 | filing |
| 23 Jun 2025filed 25 Jun 2025 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 28 Jun 2024filed 2 Jul 2024 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Code A | $14K4,854 at $2.96 | filing |
| 24 Jun 2024filed 26 Jun 2024 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 29 Dec 2023filed 3 Jan 2024 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Code A | $287167 at $1.72 | filing |
| 30 Jun 2023filed 5 Jul 2023 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Code A | $266167 at $1.59 | filing |
| 30 Dec 2022filed 3 Jan 2023 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Code A | $4505,000 at $0.09 | filing |
| 17 Aug 2022filed 18 Aug 2022 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Bought | $102K600,000 at $0.17 | filing |
| 30 Jun 2022filed 15 Jul 2022 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Code A | $3,7505,000 at $0.75 | filing |
| 12 May 2022filed 16 May 2022 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 12 May 2022filed 16 May 2022 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Code M | $100K100,000 at $1.00 | filing |
| 1 Mar 2022filed 3 Mar 2022 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 31 Dec 2021filed 3 Jan 2022 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Code A | $6,0143,623 at $1.66 | filing |
| 30 Jun 2021filed 2 Jul 2021 | VTGN Vistagen TherapeuticsBiotechnology | SEC FORM 4 Code A | $9,7505,000 at $1.95 | filing |
News
No headline names them, or the companies they trade most, lately.